Argo will receive an upfront payment of $160 million, an option for Profit & Loss split across multiple geographies and potential near-term equity
The identified products for Active Pharmaceutical Ingredients (API) will be developed under the CRAMS and CDMO models
The two-year agreement will grant Lonza access to IBF's prominent network and allow IBF to benefit from Lonza's manufacturing expertise and knowledge in its due diligence review of potential targets
New line of Waters MaxPeak Premier columns further enhances the analysis by delivering 2x to 3x greater sensitivity than conventional steel columns
The researchers are of the view that the new drug designing strategy demonstrated by them could also be adopted to treat retroviral infections.
The extended collaboration will provide services relating to small molecules for both Forbion and BGV portfolio companies active in the biopharmaceutical space
The tie-up combines Abbisko Therapeutics’ proprietary drug discovery platform with Lilly’s disease and discovery expertise
IND application for EB-003 expected in early 2026
Ascletis announces ultra-long-acting subcutaneous depot maintenance formulation of small molecule GLP-1R agonist ASC30 with 75-Day observed half-life in participants with obesity
Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines
Subscribe To Our Newsletter & Stay Updated
